Innomed Technologies, Inc. Welcomes Industry Heavy Hitter; Mergenet Solutions, Inc. Partners With First Atlantic Corporation

Wednesday, September 19, 2001

BOCA RATON, Fla.--(BUSINESS WIRE)--Sept. 19, 2001--

Innomed Technologies, Inc., in its quest to sizably impact the "enormous" world sleep apnea market, has added Karen Rasmussen to head the companies U.S. west coast efforts. Ms. Rasmussen brings over 2 decades of clinical sleep and respiratory product experience. Her valuable expertise centers on marketing, training, and sales. Innomed Technologies, Inc. revolutionary "Nasal Aire" sleep apnea interface is expected to go head to head with the latest offerings from competitors Resmed (RMD) and Respironics (RESP). It's felt the addition of Ms. Rasmussen will add important new dimensions to Innomed Technologies, Inc.'s extensive veteran management foundation.
Additionally, Innomed Technologies, Inc.'s parent company, Mergenet Solutions, Inc., has partnered with First Atlantic Corporation in order to assist the Boca Raton based Medical and Technology incubator with its venture capital needs.

About Mergenet Solutions, Inc.

Mergenet Solutions, Inc. is a full service technology incubator based in Boca Raton, Florida. The company also can assist private companies in their efforts to become public, as well as ancillary services, such as providing a board of directors, constructing company advisory boards, private placements, etc.
The company at present has several companies under incubation and accepts applications at the company's web site www.mergenetsolutions.com.  Mergenet Solutions concentrates on technology, medical technology, and energy related companies.

About Innomed Technologies, Inc.

Innomed Technologies, Inc. is a 21st Century medical technologies company. The company is poised to bring new and more effective medical products and devices to the public through a medical development and engineering team as well as acquisitions of other medical related companies. Innomed Technologies, Inc. has primarily been a research oriented, privately held, medical technology development company for the past 4 years. The company owns a full utility patent and patents pending.

A Private Securities Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Certain information included in this press release (as well as information included in written statements to be made) contain statements that are forward-looking, such as those relating to consummation of the transaction, anticipated future revenue of the Company's and success of current public offerings. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future and, accordingly, such results may differ materially from those expressed in any forward looking statements.